Citigroup
VTGN icon

Citigroup’s VistaGen Therapeutics VTGN Stock Holding History

Citigroup’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864 Buy
3,822
+3,821
+382,100% +$2.31K ﹤0.01% 5420
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 5876
2025
Q4 		– Sell
-3,453
Closed -$12.3K – 6513
2025
Q3 		$12.3K Sell
3,453
-86
-2% -$257 ﹤0.01% 4958
2025
Q2 		$7.08K Buy
3,539
+3,536
+117,867% +$8.03K ﹤0.01% 5238
2025
Q1 		$8 Hold
3
– – ﹤0.01% 5497
2024
Q4 		$9 Sell
3
-1,226
-100% -$3.45K ﹤0.01% 5775
2024
Q3 		$3.7K Buy
1,229
+1,226
+40,867% +$4.18K ﹤0.01% 5366
2024
Q2 		$10 Sell
3
-34,903
-100% -$151K ﹤0.01% 5520
2024
Q1 		$184K Sell
34,906
-23,471
-40% -$113K ﹤0.01% 4056
2023
Q4 		$300K Buy
58,377
+58,336
+142,283% +$221K ﹤0.01% 3723
2023
Q3 		$214 Hold
41
– – ﹤0.01% 5314
2023
Q2 		$76 Buy
41
+36
+720% +$126 ﹤0.01% 5465
2023
Q1 		$19 Sell
5
-47
-90% -$246 ﹤0.01% 5379
2022
Q4 		$161 Sell
52
-47
-47% -$177 ﹤0.01% 5611
2022
Q3 		$0 Sell
99
-338
-77% -$3.35K ﹤0.01% 6356
2022
Q2 		$12K Buy
437
+197
+82% +$6.96K ﹤0.01% 5294
2022
Q1 		$9K Sell
240
-13,511
-98% -$589K ﹤0.01% 5599
2021
Q4 		$804K Buy
13,751
+7,916
+136% +$515K ﹤0.01% 3460
2021
Q3 		$480K Buy
5,835
+5,531
+1,819% +$481K ﹤0.01% 3644
2021
Q2 		$29K Sell
304
-1,438
-83% -$107K ﹤0.01% 5109
2021
Q1 		$111K Buy
+1,742
New +$116K ﹤0.01% 4318

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

Citigroup's VTGN Position: Q2 2026 in Review

Citigroup increased its VistaGen Therapeutics (VTGN) stake by 382,100% in Q2 2026, buying an estimated $2.31K and bringing the position to 3,822 shares worth $864. The position accounts for ﹤0.01% of the portfolio, ranked #5420.

Citigroup first reported a position in VTGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $804K in Q4 2021. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Citigroup held 3,822 shares of VistaGen Therapeutics worth $864 as of Q2 2026.
  • Citigroup bought 3,821 VistaGen Therapeutics shares in Q2 2026, an estimated $2.31K.
  • VistaGen Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5420 holding.
  • Citigroup first reported a position in VistaGen Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Citigroup's VistaGen Therapeutics position peaked at $804K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.